Vaccine Contract Manufacturing Market Overview
Edward Jenner discovered the vaccine in west in 1796 with vaccinia virus inoculated in 13 year old boy. First smallpox vaccine was developed in 1798. A mild form of a disease which is injected into person or animal blood using an injection for protection of body against the disease is called as ‘vaccine’. Vaccine is the preparation used for stimulating body’s immune response against the disease. Vaccine are also administered by mouth and sprayed into nose. Inoculation is the other word for vaccine. Main types of vaccines are inactivated vaccines, live-attenuated vaccines, recombinant vaccines, polysaccharide vaccines, conjugate vaccines and subunit vaccines. Vaccine is the public health interventions used in preventing complications, reducing disease spread, etc. Vaccine helps body in creating protective antibodies that is the proteins which helps in fighting off infections. Getting vaccinated gives protection and avoid spreading of preventable diseases from one people to other in community. Vaccine helps immune system to fight with infections more effectively and faster. Serious diseases like polio, rubella, tetanus are preventable by vaccine and help people saving from huge medical bills and painful treatment process. If an individual get vaccinated early it will help in preventing such diseases and thus increase life expectancy of an individual. Vaccine is an active immunity acquired through introduction of weakened or killed form of disease organism through vaccination. Vaccine has become important in healthcare in preventing disease outspread and thus given positive impact on Vaccine Contract Manufacturing market growth.
|
Attributes |
Details |
|
Vaccine Contract Manufacturing Market Value (2022) |
US$ 2.5 Mn |
|
Vaccine Contract Manufacturing Market Projected Value (2032) |
US$ 6.50 Mn |
|
Vaccine Contract Manufacturing Market CAGR (2022 – 2032) |
10.2% |
Vaccine Contract Manufacturing Market Dynamics
Rise in prevalence of disease and rate of urbanization
Rise in prevalence of disease and rate of urbanization is one of the leading factors for the Vaccine Contract Manufacturing Market growth. Urbanization has given rise in consumption of western food, processed food, frozen packed foods, which are unhealthy and affected the health of human being. Urbanization has given rise in disposable income which allows the individual to enhance their lifestyle, consuming high amount of red meat and animal derived food, fats & oils, sugar, sodium, alcohol intake, smoking which has affected the health and has given rise in prevalence of disease. Urbanization has caused change in diet, water pollution, air pollution due to increased number of vehicles and residential population. Urbanization has affected health condition due to emergence of infectious diseases, pollution related health conditions, inadequate house condition and consumption of poor nutrition food. Due to rapid urbanization there is rise in overcrowded settlements, inadequate housing conditions, and lack of infrastructure for water and sanitation which has caused higher risk of infectious diseases. Inadequate hygiene at fast food stalls, rising consumption of unhealthy fast food has given rise in infectious diseases. For example, Typhoid and Cholera are transmitted through water and food contaminated with human faeces which contains pathogen Urbanization has given rise in emergence and spread of arboviral disease like Zika virus, Chikungunya, Dengue which are highly adapted in urban areas. Highly connected urban areas and dense areas has become major hotspot in outbreak of disease like SARS and COVID-19. Vaccine helps in preventing disease and increase immunity power and thus has become important in prevention and spread of disease. According to data published by United Nations in 2018, about 55% of the world’s population resided in urban areas, and it is projected that this percentage will increase over the forecast period. However, the growth in prevalence of disease and population in urban areas boosts the demand for Vaccine Contract Manufacturing market.
Change in environmental conditions and rise in zoonotic diseases
Change in environmental conditions and rise in zoonotic diseases has become the major factor in target market growth. Zoonosis is the infectious disease transmitted from animals to human being. Change in climatic conditions has played major role in risk of spread of pathogens. Change in environmental conditions has affected species range and density which has led to increase in risk of emergence of zoonotic disease. Climate change causes prolonged vegetation growth, broadening habitat, fluctuating temperatures which provides favorable living conditions by promoting reproduction and survival growth in zoonotic pathogens and vectors. For example, in 1993 the emergence of pulmonary hantavirus caused by upsurge of rodent population due to long period of drought followed by extremely high precipitation. The population of black flying fox in Australia which was key reservoir of Hendra virus was moved 100 km southward in past 100 years due to climatic change. This Hendra virus was spread to southern horse population and thus human being were infected subsequently by horses. For instance, in 2022, (PMC), determined that climate change has given rise in zoonotic diseases. Zoonosis transmission of infections from animals to human beings has reached 60% of total infectious diseases. Climatic changes has caused variation in rainfall patterns, temperature, climatic disaster, has allowed favorable conditions for increase in vector-borne diseases. High rainfall and flooding has favored transmission of water-borne diseases. Zoonosis has become the global threat because they can become pandemic as seen during COVID-19. Global climatic changes has influenced transmission of diseases among world population due to rising transmission rate of vector-borne diseases. Development of vaccines is much more needed to prevent the outbreak of diseases which will led in rising manufacture of vaccines. However, the changing environmental conditions and rising zoonotic diseases has become boost growth in Vaccine Contract Manufacturing market.
Restrains:
However, complexity, economic growth opportunity, and high fixed cost of vaccine manufacturing, inconsistent demand, high cost and time for production of broad portfolio, lack of supply may somewhat restrain the Vaccine Contract Manufacturing market growth.
Vaccine Contract Manufacturing Market Segmentation
:
Vaccine Contract Manufacturing Market is segmented based on type, workflow, application, and region.
Type Insight
On the basis of Type Vaccine Contract Manufacturing Market is segmented into Inactivated Vaccines, Messenger RNA Vaccines, Viral Vector Vaccines, Conjugate Vaccines, Live-attenuated Vaccines, and others.
Workflow Insights
On the basis of Workflow Vaccine Contract Manufacturing Market is segmented into Upstream Process, Downstream Process.
Application Insights
On the basis of Application Vaccine Contract Manufacturing Market is segmented into Veterinary and Human Use. Vaccine use in human being has dominated the market due to rising prevalence of disease in humans.
Regional Insights:
Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.
On region the Vaccine Contract Manufacturing Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period, owing to growing population, especially in countries such as Europe and Asia Pacific, and technological advancements. Moreover, rising prevalence of infectious diseases like chickenpox, hepatitis-B, measles, etc. and rising presence of pharmaceutical and biopharmaceutical companies for clinical research studies is anticipated to increase demand for Vaccine Contract Manufacturing in the region.
Report Scope:
|
Attribute |
Details |
|
Base year for estimation |
2022 |
|
Forecast period |
2022 – 2032 |
|
Market representation |
Revenue in USD Billion & CAGR from 2022 to 2032 |
|
Market Segmentation |
By Type - Inactivated Vaccines, Messenger RNA Vaccines, Viral Vector Vaccines, Conjugate Vaccines, Live-attenuated Vaccines, and others By Workflow - Upstream Process, Downstream Process By Application - Veterinary, Human Use
|
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032. For the purpose of this study, has segmented the Vaccine Contract Manufacturing Market report based on type, workflow, application, and region:
Vaccine Contract Manufacturing Market, By Type:
- Inactivated Vaccines
- Messenger RNA Vaccines
- Viral Vector Vaccines
- Conjugate Vaccines
- Live-attenuated Vaccines
- Others
Vaccine Contract Manufacturing Market, By Workflow:
- Upstream Process
- Downstream Process
Vaccine Contract Manufacturing Market, By Application:
- Veterinary
- Human Use
Vaccine Contract Manufacturing Market, By Region:
-
-
- North America
-
- U.S.
- Canada
-
- Europe
-
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
-
- Asia Pacific
-
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
-
- Latin America
-
- Brazil
- Mexico
- Rest of Latin America
-
- Middle East & Africa
-
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
-
- North America
-
Vaccine Contract Manufacturing Market Key Players
The key players operating the Vaccine Contract Manufacturing Market includes,
Serum Institute of India
It is India’s no 1 biotechnology company and manufacturer of immune-biologics, vaccines which includes, Diphtheria, Rubella, Toxoid, Measles, Hepatitis-B, Toxoid and others.
Pfizer Inc.
It is the reliable multinational vaccine producer and one of the largest supplier of sterile injectables in the world.
GlaxoSmithKline
It is the manufacturer of consumer health products, vaccines and prescribed medications.
Ajinomoto BioPharma
It is the manufacturer of vaccine for infectious diseases and medicines for genetic diseases, heart diseases, cancer, liver, lungs, eye, etc.
Merck & Co. Inc.,
It is an American pharmaceutical company in New Jersey. It provides rubella vaccine, mumps vaccine, and main trivalent measles.
AstraZeneca Plc.
It is the British-Swedish multinational pharmaceutical and biotechnology company. It is known for developing Oxford-AstraZeneca COVID-19 vaccine.
Moderna Inc.
It is an American pharmaceutical and biotechnology company in Cambridge Massachussets. It focuses on vaccine technologies based on messenger RNA, drug development and drug discovery.
Fujifilm Diosynth Biotechnologies
It is the global leader in process development for recombinant vaccines and viral vectors.
Catalent
It is the developer and manufacturer of vaccines for protection against variety of infectious diseases and chronic diseases.
Emergent BioSolutions Inc.
It is the developer and manufacturer of innovative vaccines and therapeutics.
Kemwell Biopharma
It provides product development, customized process, and manufacturing solutions in biopharmaceutical organizations worldwide.
Samsung Biologics Co. Ltd.
It offers wide range of services from process development, cell line development, manufacturing of clinical and non-clinical material.
Recent Development:
- In September 2022, Serum Institute of India, Department of Biotechnology, Biotechnology Industry Research Assistance Council and Bill and Melinda Gates Foundation partnership has announced the India’s first qHPV vaccine (Quadrivalent Human Papillomavirus Vaccine) ’CERVAVAC’ for prevention of cervical cancer. This newly launched cost effective and affordable vaccine has taken India a step closer to PM Modi’s vision of ‘Atmanirbhar Bharat’.
- In June 2022, Emergent BioSolutions Inc., has announced publication of CHIKV VLP (chikungunya virus virus-like particle) phase 2 safety and immunogenicity data in ‘The Lancet Infectious Diseases’. New CHIKV VLP vaccine in candidate was determined to be well tolerated and also induced a durable and robust serum neutralizing antibody immune response against Chikungunya virus for two years.
Vaccine Contract Manufacturing Market Company Profile
- Serum Institute of India *
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Pfizer Inc.
- GlaxoSmithKline
- Ajinomoto BioPharma
- Merck & Co. Inc.
- AstraZeneca Plc.
- Moderna Inc.
- Fujifilm Diosynth Biotechnologies
- Catalent
- Emergent Biosolutions Inc.*
- Kemwell Biopharma
- Samsung Biologics Co. Ltd.
“*” marked represents similar segmentation in other categories in the respective section
Vaccine Contract Manufacturing Market Table of Contents
- Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years Considered for the study
- Assumptions
- Abbreviations
- Research Methodology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Sources
- Key Thickness Insights
- Secondary Data
- Major Secondary Sources
- Secondary Sources
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
- Market Purview
- Executive Summary
- Key Findings—Global Outlook for medical carts Strategies
- Key Questions this Study will Answer
- Market Snippet, By Type
- Market Snippet, By Workflow
- Market Snippet, By Application
- Market Snippet, By Region
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restrains
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Dynamics
- Global Vaccine Contract Manufacturing Market, By Type
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
- Y-o-Y Growth Analysis (%), 2022 – 2032
- Segment Trends
- Inactivated Vaccines
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
- Messenger RNA Vaccines
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
- Viral Vector Vaccines
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
- Conjugate Vaccines
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
- Live-attenuated Vaccines
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
- Others
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
- Overview
- Global Vaccine Contract Manufacturing Market, By Workflow, 2022 – 2032, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
- Y-o-Y Growth Analysis (%), 2022 – 2032
- Segment Trends
- Upstream Process
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
- Downstream Process
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
- Overview
- Global Vaccine Contract Manufacturing Market, By Application, 2022 – 2032, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
- Y-o-Y Growth Analysis (%), 2022 – 2032
- Segment Trends
- Veterinary
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
- Human Use
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
- Overview
- Global Vaccine Contract Manufacturing Market, By Region, 2022 – 2032, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
- Y-o-Y Growth Analysis (%), 2022 – 2032
- Regional Trends
- North America
- Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
- Market Size and Forecast (US$ Bn), By Workflow, 2022 – 2032
- Market Size and Forecast (US$ Bn), By Application, 2022 – 2032
- Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
- Market Size and Forecast (US$ Bn), By Workflow, 2022 – 2032
- Market Size and Forecast (US$ Bn), By Application, 2022 – 2032
- Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
- UK
- France
- Germany
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
- Market Size and Forecast (US$ Bn), By Workflow, 2022 – 2032
- Market Size and Forecast (US$ Bn), By Application, 2022 – 2032
- Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
- India
- Japan
- South Korea
- China
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
- Market Size and Forecast (US$ Bn), By Workflow, 2022 – 2032
- Market Size and Forecast (US$ Bn), By Application, 2022 – 2032
- Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
- Overview
-
-
-
- Brazil
- Mexico
- Rest of Latin America
-
- Middle East & Africa
- Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
- Market Size and Forecast (US$ Bn), By Workflow, 2022 – 2032
- Market Size and Forecast (US$ Bn), By Application, 2022 – 2032
- Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
-
-
-
-
- GCC
- Israel
- South Africa
- Rest of Middle East
-
-
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Company Profiles
- Serum Institute of India
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- GlaxoSmithKline
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Ajinomoto BioPharma
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Merck & Co. Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- AstraZeneca Plc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Moderna Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Fujifilm Diosynth Biotechnologies
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Catalent
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Emergent Biosolutions Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Kemwell Biopharma
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Samsung Biologics Co. Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- The Last Word
- Future Impact
- About Us
- Contact
FAQs
The Vaccine Contract Manufacturing Market is segmented into type, workflow, application, and region.
Vaccine Contract Manufacturing Market is driven by factors like rise in prevalence of disease, rate of urbanization, change in environmental conditions and rising zoonotic diseases.
By region, the Vaccine Contract Manufacturing market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period, owing to growing population, especially in countries such as Europe and Asia Pacific, and technological advancements.
The key players operating the Vaccine Contract Manufacturing Market includes, Serum Institute of India, Pfizer Inc., GlaxoSmithKline, Ajinomoto BioPharma, Merck & Co. Inc., AstraZeneca Plc., Moderna Inc., Fujifilm Diosynth Biotechnologies, Catalent, Emergent Biosolutions Inc., Kemwell Biopharma, Samsung Biologics Co. Ltd., and others.